# Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

> **NCT01827540** · PHASE1 · COMPLETED · sponsor: **Tobira Therapeutics, Inc.** · enrollment: 20 (actual)

## Conditions studied

- HIV-infection/AIDS

## Interventions

- **DRUG:** Cenicriviroc
- **DRUG:** Dolutegravir
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT01827540
- **Lead sponsor:** Tobira Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2014-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827540, "Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01827540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*